A detailed history of Ken Griffin (Citadel Advisors LLC) transactions in Merus N.V. stock. As of the latest transaction made, Citadel Advisors LLC holds 23,300 shares of MRUS stock, worth $1.09 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
23,300
Previous 33,800 31.07%
Holding current value
$1.09 Million
Previous $2 Million 41.77%
% of portfolio
0.0%
Previous 0.0%

Shares

17 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$47.19 - $58.84 $1.76 Million - $2.2 Million
37,366 Added 20.55%
219,219 $11 Million
Q2 2024

Aug 14, 2024

SELL
$39.81 - $60.2 $6.78 Million - $10.3 Million
-170,355 Reduced 48.37%
181,853 $10.8 Million
Q1 2024

May 15, 2024

BUY
$28.03 - $51.82 $2.02 Million - $3.73 Million
71,957 Added 25.68%
352,208 $15.9 Million
Q4 2023

Feb 14, 2024

BUY
$20.06 - $28.66 $5.56 Million - $7.94 Million
277,066 Added 8699.09%
280,251 $7.71 Million
Q3 2023

Nov 14, 2023

SELL
$20.13 - $27.29 $1.67 Million - $2.27 Million
-83,099 Reduced 96.31%
3,185 $75,000
Q2 2023

Aug 14, 2023

SELL
$18.33 - $27.18 $1.08 Million - $1.61 Million
-59,175 Reduced 40.68%
86,284 $2.27 Million
Q1 2023

May 15, 2023

BUY
$14.25 - $20.5 $1.25 Million - $1.79 Million
87,533 Added 151.11%
145,459 $2.68 Million
Q4 2022

Feb 14, 2023

SELL
$12.8 - $23.66 $100,416 - $185,612
-7,845 Reduced 11.93%
57,926 $896,000
Q3 2022

Nov 14, 2022

BUY
$18.64 - $28.93 $926,631 - $1.44 Million
49,712 Added 309.56%
65,771 $1.32 Million
Q2 2022

Aug 15, 2022

SELL
$13.98 - $29.25 $9.26 Million - $19.4 Million
-662,676 Reduced 97.63%
16,059 $364,000
Q1 2022

May 16, 2022

BUY
$23.58 - $30.91 $1.92 Million - $2.52 Million
81,393 Added 13.63%
678,735 $17.9 Million
Q4 2021

Feb 14, 2022

BUY
$20.0 - $32.29 $8.38 Million - $13.5 Million
419,152 Added 235.23%
597,342 $19 Million
Q3 2021

Nov 15, 2021

SELL
$16.48 - $27.23 $584,150 - $965,194
-35,446 Reduced 16.59%
178,190 $3.92 Million
Q2 2021

Aug 16, 2021

BUY
$20.0 - $25.48 $3.26 Million - $4.15 Million
162,986 Added 321.79%
213,636 $4.5 Million
Q1 2021

May 17, 2021

BUY
$16.14 - $29.11 $817,491 - $1.47 Million
50,650 New
50,650 $1.06 Million
Q3 2020

Nov 16, 2020

SELL
$10.57 - $16.0 $217,372 - $329,040
-20,565 Closed
0 $0
Q2 2020

Aug 14, 2020

BUY
$10.5 - $17.36 $215,932 - $357,008
20,565 New
20,565 $331,000

Others Institutions Holding MRUS

About Merus N.V.


  • Ticker MRUS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 45,878,200
  • Market Cap $2.14B
  • Description
  • Merus N.V., a clinical-stage immuno-oncology company, engages in the discovery and development of bispecific antibody therapeutics in the Netherlands. Its bispecific antibody candidate pipeline includes Zenocutuzumab (MCLA-128), which is in a phase 2 clinical trials for the treatment of patients with metastatic breast cancer, as well as in Phase...
More about MRUS
Track Ken Griffin's Portfolio

Track Ken Griffin Portfolio

Follow Ken Griffin (Citadel Advisors LLC) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.